Vancouver, BC, June 02, 2025 (GLOBE NEWSWIRE) -- New Wave Holdings Corp. (“New Wave” or the “Company”) (CSE:NWAI, FWB:0XM0, OTCPK:TRMNF) announces that Mr. Joshua Matettore has been appointed as Chief Executive Officer (“CEO”) of the Company effective immediately. Mr. Matettore succeeds Mr. Sunny Ray as CEO, following Mr. Ray’s resignation from the role, which the Company accepted effective today. Mr. Ray will remain a Director of the Company and will continue to work closely with the Company’s management t ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Vancouver, BC (June 2, 2025) – Miata Metals Corp. (CSE: MMET) (FSE: 8NQ) (OTCQB:MMETF) (“Miata” or the “Company”) is pleased to announce that it has entered into an option agreement (the “Nassau Agreement”) with the registered owner (the “Optionor”) of the Nassau gold project in Suriname (“Nassau”), providing a path to increase the 70% interest currently held by the Company to 100%. “With this transaction, Miata now holds exposure to the potenti ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving multiple doses of INB-200 exceeds th ...

Dr Manfred Knof Dr. Manfred Knof, former Commerzbank CEO, joins DeFi Technologies as Strategic Advisor and Chairman of Valour, bringing decades of leadership in European banking. DeFi Technologies appoints former Commerzbank CEO Dr. Manfred Knof as Strategic Advisor to DeFi Technologies and Chairman of Valour, bringing decades of executive leadership experience in European banking and finance.Dr. Knof will drive global growth and institutional expansion for Valour by leveraging his extensive industry ne ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, June 02, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops cutting-edge data centers, is pleased to provide unaudited comparative Bitcoin (“BTC”) production results for the month ended May 31, 2025, ...

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and tes ...

Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced drug discoverers, developers, and innovators dedicated to applying advances in genetic medicine [3] Upcoming Event - Members of BridgeBio's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9 at 8:40 am ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]

Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients in the literatureMeaningful Clinical Benefit observed in all MBC subtypes, including HER2+, HR+/HER2-, and triple-negative breast cancer (TNBC)Overall survival and clinical benefit data repo ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil Engineer with over forty years of experience in leading positions in the Chilean mining, energy, and civil society sectors. Most recently, Mr. Cruz was Executive Chair of TECHO International, Latin America’s largest NGO with operations in 19 countries. Before ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, Mr. Jorge Paradela, that the Junta de Andalucia, through his ministry, has granted the exploitation license to Minera Los Frailes (“MLF”) to develop the Aznalcollar project. Spanish independent legal counsel of Emerita has reassured the Company that this a ...